TissueTech has selected the Medidata Rave Clinical Cloud as its end-to-end platform for conducting clinical trials.

The partnership will enable TissueTech to transform in biologics with a focus on regenerative therapies derived from human birth tissue for patients suffering from serious unmet clinical needs.

TissueTech will use the industry’s end-to-end unified platform which includes Medidata Rave EDC, RTSM, CTMS, eTMF, and eCOA to create a single source of truth from study planning till completion.

The company can optimise operational execution and improve quality, while decreasing the number of e-clinical systems used across study teams.

Medidata’s unified platform, Rave Clinical Cloud, allows TissueTech to focus on intelligent oversight of study, country and site activities.

TissueTech president and CEO Amy Tseng: “The partnership with Medidata further underscores TissueTech’s commitment to evidence-based medicine, scientific integrity and continuous research and innovation.

“Medidata’s unified platform provides us with the technology foundation to scale our clinical research, address the complexity of today’s clinical trials, and build and maintain efficiencies as we continue to grow.”

Medidata’s partnership will also enable TissueTech to strengthen its business processes through automatic capture and harmonisation of data from multiple sources to power organised study execution.

The collaboration will also allow TissueTech to provide faster access and real-time visibility into medical images for secure and cost-effective management.

Medidata co-founder and president Glen de Vries: “TissueTech has pioneered the clinical application of human placental tissues, and we’re proud to be part of their journey in developing regenerative therapies for ocular disease, complex wounds, osteoarthritis of the knee, and other patient needs.”